Literature DB >> 8941230

Renal complications in HIV disease.

T K Rao1.   

Abstract

Renal consequences of HIV disease are diverse: some unique attributable to HIV infection per se and some coincidental reflecting the nature and severity of underlying primary illness. In addition, renal sequelae may also be iatrogenic, owing to a variety of therapeutic agents employed in the management of HIV infection. Renal failure from any cause, both reversible (acute) and irreversible (ESRD), contributes greatly to morbidity and mortality in HIV-infected patients. An understanding of the spectrum of renal derangements is essential for clinicians to manage patients with HIV disease better.

Entities:  

Mesh:

Year:  1996        PMID: 8941230     DOI: 10.1016/s0025-7125(05)70497-1

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  5 in total

1.  Thrombotic microangiopathy in the HIV-2-infected macaque.

Authors:  F Eitner; Y Cui; K L Hudkins; A Schmidt; T Birkebak; M B Agy; S L Hu; W R Morton; D M Anderson; C E Alpers
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

Review 2.  HIV-associated immune complex kidney disease.

Authors:  Ehsan Nobakht; Scott D Cohen; Avi Z Rosenberg; Paul L Kimmel
Journal:  Nat Rev Nephrol       Date:  2016-01-19       Impact factor: 28.314

3.  Tubular cell phenotype in HIV-associated nephropathy: role of phospholipid lysophosphatidic acid.

Authors:  Kamesh R Ayasolla; Partab Rai; Shai Rahimipour; Mohammad Hussain; Ashwani Malhotra; Pravin C Singhal
Journal:  Exp Mol Pathol       Date:  2015-06-14       Impact factor: 3.362

4.  HIV gene expression deactivates redox-sensitive stress response program in mouse tubular cells both in vitro and in vivo.

Authors:  Divya Salhan; Shresh Pathak; Mohammad Husain; Pranai Tandon; Dileep Kumar; Ashwani Malhotra; Leonard G Meggs; Pravin C Singhal
Journal:  Am J Physiol Renal Physiol       Date:  2011-10-12

5.  Steady-state pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with end-stage renal disease receiving chronic dialysis.

Authors:  Paul R Bohjanen; Melissa D Johnson; Lynda A Szczech; Dannah W Wray; William P Petros; Cameron R Miller; Charles B Hicks
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.